Kapplingattu S, Bhattacharya S, Adlakha Y
Cell Death Discov. 2025; 11(1):7.
PMID: 39805813
PMC: 11729916.
DOI: 10.1038/s41420-024-02283-x.
Alshammari Q, Alshammari S, Alshammari A, Alfarhan M, Baali F
Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39476245
DOI: 10.1007/s00210-024-03564-z.
Zhang Y, Liu S, Wu C, Gao X, Zhao H, Li O
J Cell Mol Med. 2024; 28(18):e70098.
PMID: 39307884
PMC: 11416905.
DOI: 10.1111/jcmm.70098.
Lucchini S, Constantinou M, Marino S
Mol Oncol. 2024; 18(12):2871-2889.
PMID: 39148319
PMC: 11619803.
DOI: 10.1002/1878-0261.13706.
Seyhan A
Int J Mol Sci. 2024; 25(14).
PMID: 39063215
PMC: 11277426.
DOI: 10.3390/ijms25147974.
Integrated microRNA and proteome analysis of cancer datasets with MoPC.
Lovino M, Ficarra E, Martignetti L
PLoS One. 2024; 19(3):e0289699.
PMID: 38512819
PMC: 10956802.
DOI: 10.1371/journal.pone.0289699.
Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma.
Valle-Garcia D, la Cruz V, Flores I, Salazar A, Pineda B, Meza-Sosa K
Int J Mol Sci. 2024; 25(5).
PMID: 38473710
PMC: 10931459.
DOI: 10.3390/ijms25052464.
C-Myc/H19/miR-29b axis downregulates nerve/glial (NG)2 expression in glioblastoma multiforme.
Boewe A, Wrublewsky S, Hoppstadter J, Gotz C, Kiemer A, Menger M
Mol Ther Nucleic Acids. 2024; 35(1):102120.
PMID: 38318212
PMC: 10839451.
DOI: 10.1016/j.omtn.2024.102120.
Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies.
Tluli O, Al-Maadhadi M, Al-Khulaifi A, Akomolafe A, Al-Kuwari S, Al-Khayarin R
Cancers (Basel). 2023; 15(17).
PMID: 37686489
PMC: 10486509.
DOI: 10.3390/cancers15174213.
A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Hasan H, Afzal M, Castresana J, Shahi M
Cells. 2023; 12(12).
PMID: 37371047
PMC: 10297163.
DOI: 10.3390/cells12121578.
microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review.
Makowska M, Smolarz B, Romanowicz H
Int J Mol Sci. 2023; 24(4).
PMID: 36834933
PMC: 9965735.
DOI: 10.3390/ijms24043521.
Meta-Analysis of RNA-Seq Datasets Identifies Novel Players in Glioblastoma.
Sallam M, Mysara M, Baatout S, Guns P, Ramadan R, Benotmane M
Cancers (Basel). 2022; 14(23).
PMID: 36497269
PMC: 9737249.
DOI: 10.3390/cancers14235788.
MicroRNA and mRNA Expression Changes in Glioblastoma Cells Cultivated under Conditions of Neurosphere Formation.
Dymova M, Vasileva N, Kuligina E, Savinovskaya Y, Zinchenko N, Ageenko A
Curr Issues Mol Biol. 2022; 44(11):5294-5311.
PMID: 36354672
PMC: 9688839.
DOI: 10.3390/cimb44110360.
LncRNA GAS5 represses stemness and malignancy of gliomas elevating the SPACA6-miR-125a/let-7e Axis.
Wu S, Ren K, Zhao J, Li J, Jia B, Wu X
Front Oncol. 2022; 12:803652.
PMID: 36106122
PMC: 9465381.
DOI: 10.3389/fonc.2022.803652.
miR-133a-5p Inhibits Glioma Cell Proliferation by Regulating IGFBP3.
Yang X, Chen D, Hu J, Zhao Q, Fu X, Lv W
J Oncol. 2022; 2022:8697676.
PMID: 35966888
PMC: 9363926.
DOI: 10.1155/2022/8697676.
The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas.
Levallet G, Dubois F, Leclerc A, Petit E, Bekaert L, Faisant M
Int J Mol Sci. 2022; 23(11).
PMID: 35682718
PMC: 9181142.
DOI: 10.3390/ijms23116042.
Circulating miRNAs as Diagnostic and Prognostic Biomarkers in High-Grade Gliomas.
Wu J, Al-Zahrani A, Beylerli O, Sufianov R, Talybov R, Meshcheryakova S
Front Oncol. 2022; 12:898537.
PMID: 35646622
PMC: 9133847.
DOI: 10.3389/fonc.2022.898537.
Machine learning and bioinformatics approaches for classification and clinical detection of bevacizumab responsive glioblastoma subtypes based on miRNA expression.
Shi J
Sci Rep. 2022; 12(1):8685.
PMID: 35606527
PMC: 9126877.
DOI: 10.1038/s41598-022-12566-x.
Roles of the Neuron-Restrictive Silencer Factor in the Pathophysiological Process of the Central Nervous System.
Su X, Shen B, Wang K, Song Q, Yang X, Wu D
Front Cell Dev Biol. 2022; 10:834620.
PMID: 35300407
PMC: 8921553.
DOI: 10.3389/fcell.2022.834620.
Ferroptosis Involvement in Glioblastoma Treatment.
Mitre A, Florian A, Buruiana A, Boer A, Moldovan I, Soritau O
Medicina (Kaunas). 2022; 58(2).
PMID: 35208642
PMC: 8876121.
DOI: 10.3390/medicina58020319.